header logo image


Page 182«..1020..181182183184..190200..»

NOT REAL NEWS: A look at what didn’t happen this week – Associated Press

May 2nd, 2021 1:52 am

A roundup of some of the most popular but completely untrue stories and visuals of the week. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Here are the facts:

___

Posts misrepresented a report from Israel on shingles cases

CLAIM: Herpes, shingles may be a side effect of the COVID-19 vaccine.

THE FACTS: Social media posts misrepresented a report from doctors in Israel. The report from researchers at the Tel Aviv Medical Center and Carmel Medical Center describes six mostly mild cases of shingles, also known as herpes zoster, that occurred shortly after vaccination with one or two doses of the Pfizer COVID-19 vaccine. The six cases were from among 491 women with rheumatoid arthritis or related disorders who received the vaccine. The report did not establish a definite link between shingles and the vaccine. Shingles is caused by the reactivation of the virus that causes chickenpox in people who had the childhood disease. The chickenpox virus, varicella-zoster, is one of several herpes viruses. A different herpes virus causes cold sores and herpes. The report was published two weeks ago in the journal Rheumatology. Social media users subsequently posted misleading claims that the COVID-19 vaccine may cause herpes, a sexually transmitted infection. Wow, whats next? Now they given people Herpes? an Instagram user falsely wrote. In their report, the researchers said the report wasnt designed to determine if the vaccine was triggering shingles the numbers were too small, and people with rheumatoid arthritis who hadnt been vaccinated werent included. Further monitoring is warranted, they wrote. Our report does not establish any causality or definite link but draws the attention to a possible association between mrna COVID-19 vaccine and herpes zoster, Dr. Victoria Furer, lead author of the report and rheumatologist at the Tel Aviv Medical Center, told the AP in an email. Dr. William Schaffner, an infectious disease expert at Vanderbilt University, said U.S. reporting on vaccine side effects hasnt shown an increase in shingles among people whove gotten a COVID-19 vaccine. Change can happen, but at the moment, U.S. surveillance systems do not indicate that shingles is occurring more frequently in the vaccinated than in the unvaccinated population, he said. Older people and those with weakened immune systems are at higher risk for shingles, Schaffner explained. While shingles can occur at any age, chances increase after age 50. The six cases were ages 36 to 61. We have been emphasizing the vaccination of older adults, Schaffner said. Thats the very population in which shingles is the most common, and so you would expect some cases of shingles to occur after vaccination because its going to occur anyway.

Associated Press writer Arijeta Lajka in New York contributed this report

___

Study lacks evidence on masks, isnt linked to Stanford

CLAIM: A Stanford University study published on the National Institutes of Health website proves face masks are absolutely worthless against COVID-19.

THE FACTS: Websites and social media users ranging from political candidates to health influencers are falsely claiming a study published on a digital research repository came from Stanford University and proves face masks are ineffective. In reality, the study is not affiliated with Stanford, nor is the author. The study is based on debunked claims about face masks, including the false notion that wearing a face covering decreases oxygen levels and increases carbon dioxide levels. Stanford peer review study on masks says they basically do not work for C-19, the local North Dakota TV show POVNow posted on Facebook on April 19. A recent Stanford study released by the NCBI, which is under the National Institutes of Health, showed that masks do absolutely nothing to help prevent the spread of COVID-19 and their use is even harmful, read a story on the conservative website The Gateway Pundit. The story was shared widely on Facebook and Twitter last week, including by Josh Mandel, a Republican U.S. Senate candidate in Ohio. The study, titled Facemasks in the COVID-19 era: A health hypothesis, makes a variety of claims about negative health impacts of masks, including the false claim that wearing a face mask restricts breathing, leading to the conditions hypoxemia and hypercapnia. Many doctors have taken to social media to debunk claims about oxygen levels and masks, and The Associated Press also has previously debunked false claims about health risks. The study also claims there is a lack of evidence for the effectiveness of face masks in preventing the spread of COVID-19. In fact, a recent study added strong evidence that statewide mask mandates slow the spread of the coronavirus. Research shows masks block virus particles from spreading from infected people who wear them, and can even provide some protection to uninfected people who wear them. The study circulating online last week was first published in November in the journal Medical Hypotheses, which writes that its purpose is to publish interesting theoretical papers. Articles submitted to the journal are not meant to prove findings using primary data, but instead to advance hypotheses. The journal has a long history of publishing fringe science and hypotheses, according to David Gorski, a surgical oncologist who blogs about medical misinformation. The studys author, Baruch Vainshelboim, is listed in the study as being affiliated with the cardiology division at the Veterans Affairs Palo Alto Health Care System/Stanford University. However, a representative for the VA Palo Alto Health Care System told the AP in an email that Vainshelboim does not work there. I can confirm this person is not one of our physicians, wrote Michael Hill-Jackson, a public affairs specialist with the system. I do not see him in our system and our Cardiology team has never heard of him. Vainshelboim also does not work for Stanford, according to Julie Greicius, senior director of external communications for the universitys medical school. Stanford University has never employed Baruch Vainshelboim, Greicius wrote in an email to the AP. Several years ago (2015), he was a visiting scholar at Stanford for a year, on matters unrelated to this paper. Vainshelboim, who lists himself on LinkedIn as a clinical exercise physiologist and does not list any current employment, did not respond to a request for comment.

Associated Press writer Ali Swenson in Seattle contributed this report.

__

Vaccinated people can participate in Red Cross blood drives

CLAIM: The Red Cross wont accept plasma donations from people who have had a COVID-19 vaccine.

THE FACTS: The American Red Cross is accepting blood and plasma donations from those who have received COVID-19 vaccines. The Red Cross states that in most cases there is no need for donors to wait to give blood, which includes plasma, after receiving a COVID-19 vaccine as long as a donor is symptom free and feeling well. Blood donors should, however, be able to provide the name of the manufacturer of the vaccine they received when donating. Yet as more and more Americans receive COVID-19 vaccines, posts online are falsely claiming that vaccinated Americans can no longer donate plasma. The posts are part of a larger misinformation effort to falsely suggest the vaccines are dangerous. The red cross wont accept plasma donations from people who have had the covid-19 vaccine, say posts that were shared on Facebook and Twitter. Youre willing to put something in your body that is so untested that the FDA and Red Cross dont know if you can donate Plasma, yet me not wanting to take it makes me irresponsible? In fact, the posts are misstating new eligibility directives for donating convalescent plasma, which is plasma from recovered COVID-19 patients used to treat others with the illness. The Red Cross once had a dedicated program collecting convalescent plasma, but that program ended on March 26. The change happened after the U.S. Food and Drug Administration updated guidance to ensure that donations from vaccinated people would contain the antibodies needed for the convalescent plasma to be useful in treating COVID-19 patients. The Red Cross acknowledges that the U.S. Food and Drug Administration did update its guidance regarding convalescent plasma donor eligibility related to those who receive a COVID-19 vaccine, the Red Cross says on their website. We are evaluating the feasibility and timeline to implement this complex update, alongside the evolving hospital needs for COVID-19 patients. The Red Cross, however, continues to accept blood donations from people regardless of their vaccine status. All blood collected through those donations is tested for COVID-19 antibodies in case it can be used for convalescent plasma to treat patients. Due to the pandemic, the Red Cross has reported a decline in blood drives, which has created more demand for blood donations.

Associated Press writer Beatrice Dupuy in New York contributed this report.

___

Photo manipulated to make Bill Clinton appear ill

CLAIM: Photo shows former President Bill Clinton looking frail and sick, showing what happens when you sell your soul.

THE FACTS: A Facebook post shared thousands of times this week compares an official White House photo of Clinton in 1993 to a more recent photo that has been edited to make the skin around his eyes red and his irises brown. This is what happens when you sell your soul, text on the post reads. Commenters on the post likened the 74-year-old former president to Satan and speculated that he had been using drugs. A reverse-image search reveals the photo in which Clinton looks ill is not genuine. Its an edited version of a 2014 photo that appears on Getty Images, taken by photographer John Lamparski. Clinton was photographed at a Christmas benefit event in New York, according to the original photos caption. In the original photo, Clintons eyes are bright blue and the skin under his eyes is not red. Internet users have previously edited this image of Clinton to make him look like he is suffering from a debilitating disease. The manipulated images have circulated so often that the online meme dictionary Know Your Meme identifies it as a common photoshop meme that it dubs AIDS Bill Clinton or Terminally Bill.

Ali Swenson

___

Vaccine not related to Danish health officials collapse on camera

CLAIM: Video shows Denmarks top health official fainting from her COVID-19 vaccine.

THE FACTS: One of Denmarks top health officials, Tanja Erichsen, collapsed during an April 14 press conference to discuss the countrys decision to discontinue use of the AstraZeneca vaccine, but it was not related to the vaccine. She had not yet been vaccinated against the disease when she fell. The video showing the collapse of Erichsen, acting director of pharmacovigilance at the Danish Medicines Agency, is being misrepresented by anti-vaccine proponents to falsely claim that she fainted as a result of receiving the AstraZeneca shot. Her fall received international press coverage that day, but footage from the video was picked up and circulated online with the false description of what happened. Literally Denmarks top health official fainting from the COVID-19 shot, claimed one Instagram post that shared the video. Shortly after Erichsens fall, Danish Health Authority Director General Soeren Brostroem told reporters at the conference that she was OK. He said she blacked out from overwork and standing too long. A spokesperson for the Danish Medicines Agency, Kim Voigt strm, told the AP that Erichsen had yet to receive a COVID-19 vaccine despite what the posts online say. Erichsen tweeted on April 19 to say that she was feeling well and to thank everyone for their concern. Denmark has primarily relied on vaccines made by Pfizer and Moderna and will continue to use those vaccines rather than AstraZeneca. The decision to discontinue AstraZeneca came after reports of rare blood clots in some recipients.

Beatrice Dupuy

___

Photo shows art piece, not lions mane mushrooms

CLAIM: Photo shows lions mane mushrooms growing in a swamp.

THE FACTS: An image viewed more than 150,000 times on Facebook last week claims to show Lions Mane mushrooms growing from a swamp but it actually shows a work of art. Lions mane mushrooms also known as bearded tooth fungus are white with long, hanging spines, similar to the figure in the picture. They are typically about the size of a football, according to British conservation charity The Woodland Trust. A reverse-image search finds the viral image shows no fungus. Instead, its an art piece made and first exhibited in 2013 by the artist Susi Brister. The work titled 613 Silky Straight in Swamp shows a platinum blonde swamp creature slowly moving through a swampy habitat, Brister told the AP in an email. To create the image, a human model posed inside a suit created from about 100 custom-made platinum blonde hair extensions, Brister wrote. The piece is part of a larger series called Fantastic Habitat, Brister wrote, in which I create and photograph sculptural coverings worn by models in the landscape that highlight both the strange confluence and disconnection between nature and artificial nature. The work was first exhibited at Lawndale Art Center in Houston. It later appeared in other galleries in Houston and Austin, Texas. It is in no way depicting a mushroom, Brister wrote. In fact, Ive never even heard of a lions mane mushroom before, but happy to have learned something new!

Ali Swenson

___

Find AP Fact Checks here: https://apnews.com/APFactCheck

___

Follow @APFactCheck on Twitter: https://twitter.com/APFactCheck

Read this article:
NOT REAL NEWS: A look at what didn't happen this week - Associated Press

Read More...

Signs You Have an Autoimmune Disease, Like Carrie Ann Inaba | Eat This Not That – Eat This, Not That

May 2nd, 2021 1:52 am

American TV watchers were bummed on Monday when Carrie Ann Inaba, the well-known Dancing With the Stars judge and co-host of The Talk, announced she was taking a break from the afternoon chat show to deal with various health challenges, including an autoimmune condition known as Sjogren's syndrome.

Inaba's announcement was surprising, yet sadly familiar, as autoimmune disorders like lupus have increasingly become part of the public conversation in recent years; singer Selena Gomez and TV host Nick Cannon have both disclosed they suffer from that condition. Six years ago, Inaba was diagnosed with Sjogren's, an incurable immune disorder that can cause pain and fatigue. She also reportedly lives with spinal stenosis, a narrowing of the spinal canal that can cause pain and numbness, and the nerve disorder fibromyalgia.

Autoimmune disorders include a wide spectrum of issues caused when the immune system overreacts by attacking the body's own tissue. Women are more likely than men to be affected. Here are the most common signs that you're suffering from the most common autoimmune conditions. Read onand to ensure your health and the health of others, don't miss these Sure Signs Your Illness is Actually Coronavirus in Disguise.

"The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling," says the U.S. National Library of Medicine. Autoimmune diseases can affect the muscles, leading to aches that feel like you've overdone it at the gym even if you haven't left the couch.

This may be a sign of rheumatoid arthritis, a common autoimmune disorder caused when the immune system attacks the linings of the joints, causing painful swelling. Smaller joints tend to be affected first, followed by larger joints. But about 40 percent of people affected by rheumatoid arthritis experience symptoms that don't involve the joints at all. "In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels," says the Mayo Clinic.

According to the Mayo Clinic, Sjogren's syndrome is most commonly signified by dry eyes and a dry mouth, which occurs when the disorder affects the mucous membranes, drying them out. Sjogren's is often accompanied by other immune system disorders such as rheumatoid arthritis or lupus. People with Sjogren's might also experience joint pain or stiffness or swollen glands.

The experts at Johns Hopkins Medicine say that fatigue is a common symptom of autoimmune disease. "If you've been healthy and suddenly you feel fatigue or joint stiffness, don't downplay that," says Ana-Maria Orbai, M.D., M.H.S., a rheumatologist at the Johns Hopkins Arthritis Center. "Telling your doctor helps him or her to look closer at your symptoms and run tests to either identify or rule out autoimmune disease."

RELATED: The #1 Cause of Heart Attack, According to Science

Skin issues are a common sign of autoimmune disorders. A red rash on the skin, known as the "butterfly rash" is often found in lupus. In the skin condition known as psoriasis, the body's skin-production cells go into overdrive; this can cause rough, red patches or silvery scales on the skin as cells are produced faster than the body can shed them naturally. A related condition is psoriatic arthritis, in which joint pain, redness and swelling accompany the skin scaling. This is treatable with medication. Contact a medical professional if you have any of these symptoms, and to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Here is the original post:
Signs You Have an Autoimmune Disease, Like Carrie Ann Inaba | Eat This Not That - Eat This, Not That

Read More...

Rheumatoid Arthritis Drug Market Share, Trends, Business Strategy and Forecast to 2025 The Courier – The Courier

May 2nd, 2021 1:52 am

A new report titled, Global Rheumatoid Arthritis Drug Market Professional Report 2021-2025 has been added by Garner Insights in its database of research reports. The scope of the report includes a comprehensive study of global, regional, and local markets for different segments of the market. The study provides complete details about the usage and adoption of Rheumatoid Arthritis Drug in various industrial applications and geographies. This helps the key stakeholders in knowing about the major development trends, growth strategies, investments, vendor activities, and government initiatives. Moreover, the report specifies the major drivers, restraints, challenges, and lucrative opportunities that are going to impact the growth of the market.

Section (2 3): Manufacturer Detail: AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, Roche, UCB, Johnson & Johnson

Request Sample Report of Global Rheumatoid Arthritis Drug Market @https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020#request-sample

This report forecasts revenue growth at the global, regional, and local levels and provides an analysis of the most recent industry trends from 2021 to 2025 in each of the segments and sub-segments. In addition, the report highlights the impact of COVID-19 on the Global Rheumatoid Arthritis Drug Market. Some of the major geographies included in the market are given below:

Section 4: Region Segmentation: North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Section (5 6 7) :Product Type Segmentation: BiopharmaceuticalPharmaceuticals

Industry Segmentation: PrescriptionOver-the-Counter (OTC)

Grab Your Report at an Impressive Discount! Please click Here@ https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020#discount

Table of Contents: Section 1 Rheumatoid Arthritis Drug Product Definition

Section 2 Global Rheumatoid Arthritis Drug Market Manufacturer Share and Market Overview2.1 Global Manufacturer Rheumatoid Arthritis Drug Shipments2.2 Global Manufacturer Rheumatoid Arthritis Drug Business Revenue2.3 Global Rheumatoid Arthritis Drug Market Overview2.4 COVID-19 Impact on Rheumatoid Arthritis Drug Industry

Section 3 Manufacturer Rheumatoid Arthritis Drug Business Introduction3.1 AbbVie Rheumatoid Arthritis Drug Business Introduction3.1.1 AbbVie Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.1.2 AbbVie Rheumatoid Arthritis Drug Business Distribution by Region3.1.3 AbbVie Interview Record3.1.4 AbbVie Rheumatoid Arthritis Drug Business Profile3.1.5 AbbVie Rheumatoid Arthritis Drug Product Specification

3.2 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Introduction3.2.1 Boehringer Ingelheim Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.2.2 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Distribution by Region3.2.3 Interview Record3.2.4 Boehringer Ingelheim Rheumatoid Arthritis Drug Business Overview3.2.5 Boehringer Ingelheim Rheumatoid Arthritis Drug Product Specification

3.3 Novartis Rheumatoid Arthritis Drug Business Introduction3.3.1 Novartis Rheumatoid Arthritis Drug Shipments, Price, Revenue and Gross profit 2015-20203.3.2 Novartis Rheumatoid Arthritis Drug Business Distribution by Region3.3.3 Interview Record3.3.4 Novartis Rheumatoid Arthritis Drug Business Overview3.3.5 Novartis Rheumatoid Arthritis Drug Product Specification

3.4 Regeneron Pharmaceuticals Rheumatoid Arthritis Drug Business Introduction3.5 Pfizer Rheumatoid Arthritis Drug Business Introduction3.6 Bristol-Myers Squibb Company Rheumatoid Arthritis Drug Business Introduction

Section 4 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.1.2 Canada Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.2 South America Country4.2.1 South America Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3 Asia Country4.3.1 China Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.2 Japan Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.3 India Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.3.4 Korea Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4 Europe Country4.4.1 Germany Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.2 UK Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.3 France Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.4 Italy Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.4.5 Europe Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5 Other Country and Region4.5.1 Middle East Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5.2 Africa Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.5.3 GCC Rheumatoid Arthritis Drug Market Size and Price Analysis 2015-20204.6 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level) Analysis 2015-20204.7 Global Rheumatoid Arthritis Drug Market Segmentation (Region Level) Analysis

Section 5 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level)5.1 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level) Market Size 2015-20205.2 Different Rheumatoid Arthritis Drug Product Type Price 2015-20205.3 Global Rheumatoid Arthritis Drug Market Segmentation (Product Type Level) Analysis

Section 6 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level)6.1 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level) Market Size 2015-20206.2 Different Industry Price 2015-20206.3 Global Rheumatoid Arthritis Drug Market Segmentation (Industry Level) Analysis

Section 7 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level)7.1 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level) Sales Volume and Share 2015-20207.2 Global Rheumatoid Arthritis Drug Market Segmentation (Channel Level) Analysis

Section 8 Rheumatoid Arthritis Drug Market Forecast 2020-20258.1 Rheumatoid Arthritis Drug Segmentation Market Forecast (Region Level)8.2 Rheumatoid Arthritis Drug Segmentation Market Forecast (Product Type Level)8.3 Rheumatoid Arthritis Drug Segmentation Market Forecast (Industry Level)8.4 Rheumatoid Arthritis Drug Segmentation Market Forecast (Channel Level)

Section 9 Rheumatoid Arthritis Drug Segmentation Product Type9.1 Biopharmaceutical Product Introduction9.2 Pharmaceuticals Product Introduction

Section 10 Rheumatoid Arthritis Drug Segmentation Industry10.1 Prescription Clients10.2 Over-the-Counter (OTC) Clients

Section 11 Rheumatoid Arthritis Drug Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost Overview

Section 12 Conclusion

Request customized copy of report @https://garnerinsights.com/Global-Rheumatoid-Arthritis-Drug-Market-Report-2020

Go here to read the rest:
Rheumatoid Arthritis Drug Market Share, Trends, Business Strategy and Forecast to 2025 The Courier - The Courier

Read More...

EU Biologics for Rheumatoid Arthritis Treatment Market to Reach at High CAGR in Forecast Period 2019 to 2028 Clark County Blog – Clark County Blog

May 2nd, 2021 1:52 am

The EU Biologics for Rheumatoid Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the EU Biologics for Rheumatoid Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the EU Biologics for Rheumatoid Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9938

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the EU Biologics for Rheumatoid Arthritis Treatment market covers various segmentation of the EU Biologics for Rheumatoid Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the EU Biologics for Rheumatoid Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding EU Biologics for Rheumatoid Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the EU Biologics for Rheumatoid Arthritis Treatment Market

Roche, Novartis, Biogen Idec, Pfizer, Amgen, and Sanofi Pharmaceutical to invest in these products.

EU Biologics for Rheumatoid Arthritis Treatment Market Segmentation

A. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors

View Detail [emailprotected]https://insights10.com/product/eu-biologics-for-rheumatoid-arthritis-treatment-market/

Table Of Content of EU Biologics for Rheumatoid Arthritis Treatment Market

1. EU Biologics for Rheumatoid Arthritis Treatment Market Overview..A. Market Size2. Market Growth Drivers...A. Growing capital investment from the key market playersB. Growing demand and higher acceptability for innovative therapies3. Epidemiology...A. New Prevalent Cases of Rheumatoid ArthritisB. Treated cases of Rheumatoid Arthritis with Biologic drugs4. Biologics for Rheumatoid Arthritis Treatment Market SegmentationA. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors5. Biologics for Rheumatoid Arthritis Major Drugs Market ShareA. Market Analysis, Insights and Forecast to 2028 by Revenue6. Competitive Landscape.....A. Major PlayersB. Products in Pipeline7. Key Company Profiles...A. Sanofi Pharmaceutical Company overview, Product & Services, Strategies & FinancialsB. Pfizer Inc. Company overview, Product & Services, Strategies & FinancialsC. Novartis Company Profile, Product & Services, Strategies & Financials8. Potential Growth Opportunities...A. Advancements in drug developmentB. Untapped markets in developing economies9. Factors Driving Future Growth..A. Key Industry Trends and Recent Developments in Biologics for Rheumatoid Arthritis TreatmentB. Future Opportunities10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the EU Biologics for Rheumatoid Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the EU Biologics for Rheumatoid Arthritis Treatment market throughout 2019 to 2028.

More Reports

Major Depressive Disorders (MDD) Therapeutics Market Poised to Reach at High CAGR in Forecast Period 2019 to 2028EU Oral Drugs for Rheumatoid Arthritis Treatment Market Report By Sales and Revenue Analysis 2019 to 2028

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read more here:
EU Biologics for Rheumatoid Arthritis Treatment Market to Reach at High CAGR in Forecast Period 2019 to 2028 Clark County Blog - Clark County Blog

Read More...

EU Psoriatic Arthritis Treatment Market Segmentations by Application and Geography Trends, Growth and Forecasts to 2019 2028 Clark County Blog -…

May 2nd, 2021 1:51 am

The EU Psoriatic Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the EU Psoriatic Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the EU Psoriatic Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9888

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the EU Psoriatic Arthritis Treatment market covers various segmentation of the EU Psoriatic Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the EU Psoriatic Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding EU Psoriatic Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the EU Psoriatic Arthritis Treatment Market

Psoriatic Arthritis Treatment are Astra Zeneca, Novartis, Glaxo Smith Kline, Merck & Co. Inc, Takeda Pharmaceutical Company

EU Psoriatic Arthritis Treatment Market Segmentation

A. By Drug ClassI. Non-steroidal Anti-inflammatory Drugs (NSAIDS)II. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)III. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)IV. OthersB. By Route of AdministrationI. OralII. ParenteralIII. TopicalIV. InjectableC. By Distribution ChannelI. Hospitals PharmaciesII. Retail PharmaciesIII. Online Pharmacies

View Detail [emailprotected]https://insights10.com/product/eu-psoriatic-arthritis-treatment-market-analysis/

Table Of Content of EU Psoriatic Arthritis Treatment Market

1. EU Psoriatic Arthritis Treatment Market Overview..A. Market Size2. EU Psoriatic Arthritis Treatment Growth Drivers..A. Rise in Customer Awareness and Increase Disease BurdenB. Promising Pipeline and New Product Launches3. EU Psoriatic Arthritis Treatment Market Segmentation.A. By Drug ClassI. Non-steroidal Anti-inflammatory Drugs (NSAIDS)II. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)III. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)IV. OthersB. By Route of AdministrationI. OralII. ParenteralIII. TopicalIV. InjectableC. By Distribution ChannelI. Hospitals PharmaciesII. Retail PharmaciesIII. Online Pharmacies4. EU Psoriatic Arthritis Treatment Major Market Share.A. Market Analysis, Insights and Forecast by Revenue5. Competitive LandscapeA. Major PlayersB. Products in Pipeline6. Key Company Profiles..A Novartis AG Company overview, Product & Services, Strategies & FinancialsB Glaxo Smith Kline Company overview, Product & Services, Strategies & FinancialsC Astra Zeneca Company overview, Product & Services, Strategies & Financials7. Healthcare Policies and Regulatory Landscape.A. Policy Changes and Reimbursement Scenario8. Factors Driving Market GrowthA. Key Industry DevelopmentsB. Mergers and Acquisitions9. Potential Growth OpportunitiesA. Market OpportunitiesB. Future Trends10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the EU Psoriatic Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the EU Psoriatic Arthritis Treatment market throughout 2019 to 2028.

More Reports

EU Peripheral Vascular Devices Market By Study Growth Factors, Types and Applications with Forecasts 2019-2028EU Gout Therapeutics Market By Manufacturers, Types, Regions and Application and Forecast to 2028 by Global QYResearch

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read more from the original source:
EU Psoriatic Arthritis Treatment Market Segmentations by Application and Geography Trends, Growth and Forecasts to 2019 2028 Clark County Blog -...

Read More...

Global Psoriatic Arthritis Treatment Market 2019 : Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast to…

May 2nd, 2021 1:51 am

The Global Psoriatic Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the Global Psoriatic Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the Global Psoriatic Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=5598

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the Global Psoriatic Arthritis Treatment market covers various segmentation of the Global Psoriatic Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the Global Psoriatic Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding Global Psoriatic Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the Global Psoriatic Arthritis Treatment Market

AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; AstraZeneca plc; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Novartis International AG; Eli Lilly and Company; Pfizer, Inc.; and UCB S.A.

Global Psoriatic Arthritis Treatment Market Segmentation

View Detail [emailprotected]https://insights10.com/product/psoriatic-arthritis-treatment-market-analysis-2019-to-2028/

Table Of Content of Global Psoriatic Arthritis Treatment Market

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the Global Psoriatic Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the Global Psoriatic Arthritis Treatment market throughout 2019 to 2028.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read the rest here:
Global Psoriatic Arthritis Treatment Market 2019 : Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast to...

Read More...

Analyzing Impacts Of COVID-19 On Arthritis Monoclonal Antibodies Market Effects, Aftermath And Forecast To 2026 KSU | The Sentinel Newspaper – KSU |…

May 2nd, 2021 1:51 am

This report contains market size and forecasts of Arthritis Monoclonal Antibodies in Global, including the following market information:Global Arthritis Monoclonal Antibodies Market Revenue, 2016-2021, 2022-2027, ($ millions)Global top five companies in 2020 (%)

The global Arthritis Monoclonal Antibodies market was valued at XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.Research has surveyed the Arthritis Monoclonal Antibodies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Download PDF Sample of Arthritis Monoclonal Antibodies Market report @ https://www.themarketinsights.com/request-sample/131486

Total Market by Segment:Global Arthritis Monoclonal Antibodies Market, By Type, 2016-2021, 2022-2027 ($ millions)Global Arthritis Monoclonal Antibodies Market Segment Percentages, By Type, 2020 (%)RemicadeHumiraEnbrelRituxanOrenciaActemraSimponiCimzia

China Arthritis Monoclonal Antibodies Market, By Application, 2016-2021, 2022-2027 ($ millions)China Arthritis Monoclonal Antibodies Market Segment Percentages, By Application, 2020 (%)Rheumatoid ArthritisOsteoarthritisPsoriatic ArthritisAnkylosing SpondylitisFibromyalgiaOthers

Global Arthritis Monoclonal Antibodies Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)Global Arthritis Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & Africa

Report Customization available as per requirements Request Customization@ https://www.themarketinsights.com/request-customization/131486

Competitor AnalysisThe report also provides analysis of leading market participants including:Total Arthritis Monoclonal Antibodies Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)Total Arthritis Monoclonal Antibodies Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:AbbVie IncF. Hoffmann-La Roche LtdNovartisJohnson & Johnson(Janssen)Pfizer IncMylanGenentechGSKAstraZeneca PLC

To Check Discount @ https://www.themarketinsights.com/check-discount/131486

Table of ContentChapter One: Introduction to Research & Analysis Reports

Chapter Two: Global Arthritis Monoclonal Antibodies Overall Market Size

Chapter Three: Company Landscape

Chapter Four: Market Sights by Product

Chapter Five: Sights by Application

Chapter Six: Sights by Region

Chapter Seven: Players Profiles

Chapter Eight: Conclusion

Chapter Nine: Appendix9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Table and FigureTable 1. Arthritis Monoclonal Antibodies Market Opportunities & Trends in Global Market

Table 2. Arthritis Monoclonal Antibodies Market Drivers in Global Market

Table 3. Arthritis Monoclonal Antibodies Market Restraints in Global Market

Table 4. Key Players of Arthritis Monoclonal Antibodies in Global Market

Table 5. Top Arthritis Monoclonal Antibodies Players in Global Market, Ranking by Revenue (2019)

Table 6. Global Arthritis Monoclonal Antibodies Revenue by Companies, (US$, Mn), 2016-2021

Table 7. Global Arthritis Monoclonal Antibodies Revenue Share by Companies, 2016-2021

Table 8. Global Companies Arthritis Monoclonal Antibodies Product Type

Table 9. List of Global Tier 1 Arthritis Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Arthritis Monoclonal Antibodies Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 11. By Type Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 12. By Type Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2016-2021

Table 13. By Type Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2022-2027

Table 14. By Application Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 15. By Application Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2016-2021

Table 16. By Application Arthritis Monoclonal Antibodies Revenue in Global (US$, Mn), 2022-2027

Table 17. By Region Global Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2021 VS 2027

Table 18. By Region Global Arthritis Monoclonal Antibodies Revenue (US$, Mn), 2016-2021

Table 19. By Region Global Arthritis Monoclonal Antibodies Revenue (US$, Mn), 2022-2027

Table 20. By Country North America Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021

Table 21. By Country North America Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2022-2027

Table 22. By Country Europe Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021

Table 23. By Country Europe Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2022-2027

Table 24. By Region Asia Arthritis Monoclonal Antibodies Revenue, (US$, Mn), 2016-2021 continued

About us.The Market Insights is a sister company to SI Market research and The Market Insights is into reselling. The Market Insights is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between. At The Market Insights, we give our clients the best reports that can be made in the market. Our reports are not only about market statistics, but they also contain a lot of information about new and niche company profiles. The companies that feature in our reports are pre-eminent. The database of the reports on market research is constantly updated by us. This database contains a broad variety of reports from the cardinal industries. Our clients have direct access online to our databases. This is done to ensure that the client is always provided with what they need. Based on these needs, we at The Market Insights also include insights from experts about the global industries, market trends as well as the products in the market. These resources that we prepare are also available on our database for our esteemed clients to use. It is our duty at The Market Insights to ensure that our clients find success in their endeavors and we do everything that we can to help make that possible.

Direct ContactJessica Joyal+91-9284395731 | +91 9175986728sales@themarketinsights.com

Read more from the original source:
Analyzing Impacts Of COVID-19 On Arthritis Monoclonal Antibodies Market Effects, Aftermath And Forecast To 2026 KSU | The Sentinel Newspaper - KSU |...

Read More...

US Biologics for Rheumatoid Arthritis Treatment By Future Demand and Growth Analysis with Forecast 2019-2028 Clark County Blog – Clark County Blog

May 2nd, 2021 1:51 am

The US Biologics for Rheumatoid Arthritis Treatment market for the forecasting period of 2019-2028. The report is made out with a comprehensive analysis of the current market and pulled down the key factors that propel the growth of the US Biologics for Rheumatoid Arthritis Treatment market in the forecasted period. This report also encompasses key market drivers and the hindering restraints of the US Biologics for Rheumatoid Arthritis Treatment market.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=15536

This report shed its light on the markets future trend in terms of volume (Tons) and value (US$ Bn) from 2019 to 2026 with the aid of a Qualitative forecast model which works in tandem with splendid expert judgment, national government documents, statistical databases and relevant patent and regulatory databases.

Further, this report brings in the product, price, promotion, & place (i.e., 4 Ps of marketing) and their STP (Segmentation, Targeting & Positioning) of the stakeholders for a lucrative growth in the forecasted period.

This report on the US Biologics for Rheumatoid Arthritis Treatment market covers various segmentation of the US Biologics for Rheumatoid Arthritis Treatment market and analyze the market shares of those segments in the leading geographies such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of the Middle East & Africa) for the forecasted period by pinpointing the drivers and barriers of the US Biologics for Rheumatoid Arthritis Treatment market growth.

Research Methodology

The report is a collective presentation of primary and secondary research findings. That finding helps in understanding US Biologics for Rheumatoid Arthritis Treatment market dynamics, structure by identifying and analyzing the market segments and projects the market size.

Top Participants in the US Biologics for Rheumatoid Arthritis Treatment Market

oche, Novartis, Biogen Idec, Pfizer, Amgen, and Sanofi Pharmaceutical

US Biologics for Rheumatoid Arthritis Treatment Market Segmentation

A. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors

View Detail [emailprotected]https://insights10.com/product/us-biologics-for-rheumatoid-arthritis-treatment/

Table Of Content of US Biologics for Rheumatoid Arthritis Treatment Market

1. US Biologics for Rheumatoid Arthritis Treatment Market Overview..A. Market Size2. Market Growth Drivers...A. Growing capital investment from the key market playersB. Growing demand and higher acceptability for innovative therapies3. Epidemiology...A. New Prevalent Cases of Rheumatoid ArthritisB. Treated cases of Rheumatoid Arthritis with Biologic drugs4. Biologics for Rheumatoid Arthritis Treatment Market SegmentationA. By Treatment TypeI. IL-1 & IL-6 monoclonal therapyII. B-cell inhibitorsIII. T-cell inhibitorsIV. JAK inhibitorsV. TNF inhibitors5. Biologics for Rheumatoid Arthritis Major Drugs Market ShareA. Market Analysis, Insights and Forecast to 2028 by Revenue6. Competitive Landscape.....A. Major PlayersB. Products in Pipeline7. Key Company Profiles...A. Roche Company overview, Product & Services, Strategies & FinancialsB. Pfizer Inc. Company overview, Product & Services, Strategies & FinancialsC. Novartis Company Profile, Product & Services, Strategies & Financials8. Potential Growth Opportunities...A. Advancements in drug developmentB. Untapped markets in developing economies9. Factors Driving Future Growth..A. Key Industry Trends and Recent Developments in Biologics for Rheumatoid Arthritis TreatmentB. Future Opportunities10. Conclusion

Competitors Analysis

This report not only brings out the major players in the market but also pictures out the lucrative market analysis by performing various competitor assessment techniques such as SWOT analysis, PESTEL analysis, Porters five force, value chain analysis to address the question of shareholders for prioritizing the efforts and investment soon to the emerging segment in the US Biologics for Rheumatoid Arthritis Treatment market. Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the US Biologics for Rheumatoid Arthritis Treatment market throughout 2019 to 2028.

More Reports

Global Chronic Lymphocytic Leukemia Market By Study Growth Factors, Product Segments, Types and Applications with Market Forecast 2019-2028US Oral Drugs for Rheumatoid Arthritis Treatment Market By Application, Product Segment, Analysis and Forecast 2019-2028

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Read the original here:
US Biologics for Rheumatoid Arthritis Treatment By Future Demand and Growth Analysis with Forecast 2019-2028 Clark County Blog - Clark County Blog

Read More...

Psoriatic Arthritis Treatment Industry | 2021 Global Market Size, Growth and Trends Analysis By COVID-19 Impact 2021-2028 – Clark County Blog

May 2nd, 2021 1:51 am

Psoriatic Arthritis Treatment Market Analysis 2021-2028 Report provides strategists, marketers and senior management with the critical information they need to assess the global Psoriatic Arthritis Treatment market as it emerges from the Covid 19 shut down. The impact of Coronavirus (COVID-19) on Psoriatic Arthritis Treatment has reinforced many trends already shaping the industry pre-COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on multiple platforms.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. It places the market within the context of the wider Psoriatic Arthritis Treatment market, and compares it with other markets.

The market characteristics section of the report defines and explains the market. The market size section gives the market size covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.

Get Sample Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriatic-arthritis-treatment-market-101066

Why buy this report?

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.

The Impact of Coronavirus on Psoriatic Arthritis Treatment global briefing offers a comprehensive guide to the Psoriatic Arthritis Treatment market at an international level. It looks at both global and regional level performances as well as providing category and channel analysis. It identifies the leading companies and offers strategic analysis of key factors influencing the industry, new product developments as well as future trends and prospects.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified. The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

An Overview of the Impact of COVID-19 on Psoriatic Arthritis Treatment Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

The Global Psoriatic Arthritis Treatment market 2021 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Psoriatic Arthritis Treatment market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report mainly studies the size, recent trends and development status of Psoriatic Arthritis Treatment Market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing Psoriatic Arthritis Treatment Market.

Psoriatic Arthritis Treatment Market Report Intended Audience:

Psoriatic Arthritis Treatment Market Highlights:

Psoriatic Arthritis Treatment Market Report Table Of Content:

Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

Executive Summary

Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

Key Insights

Continued

Related News:

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Trends

Automotive Actuators Market Analysi

sAutomotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

Automotive Actuators Market Analysis

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune 411045, Maharashtra, India.

Phone:

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email:[emailprotected]

Psoriatic Arthritis Treatment Industry | 2021 Global Market Size, Growth and Trends Analysis By COVID-19 Impact 2021-2028

Read more:
Psoriatic Arthritis Treatment Industry | 2021 Global Market Size, Growth and Trends Analysis By COVID-19 Impact 2021-2028 - Clark County Blog

Read More...

John Stamos’ secret to longevity is to "stop trying to charm the world" – Salon

April 17th, 2021 1:54 am

Whether you know him as Blackie Parrish from "General Hospital,"Uncle Jesse from "Full House" or "ER," "Necessary Roughness," "Entourage," or "You," Emmy Award-nominated actor and producer John Stamos has been a fixture in and outside of Hollywood for decades.Though he spent years, in his own words, trying to "shed this dumb Peter Pan syndrome that I had,"Stamos has now aged gracefully into both fatherhood and roles that eschew the toxic masculinity traditionally found in films and television.

His new sports dramedy "Big Shot" is created by David E. Kelleyand featuresmany formidable female characters.Stamos says most of the writing credit goes to women."I went into the writers' room right off the bat, and I think it was about 65% women, which was great," he recalled.

On the show, Stamos playsMarvyn Korn, a top-tier basketball coach who finds himself working at an elite girls' school after getting ousted from the NCAA.Korn starts out as an arrogant, tough character who is out of his element working with teen girls, having been accustomed to working with adult male athletes.

Stamos appeared on "Salon Talks" to discuss how helikens his own personal growth in lifeas an actor to Korn's evolution to a gentler, more self-aware and thoughtful man. When Stamos started out in Hollywood, he felt pressure to look and act like a perennial bachelor."I think a lot of it came from outside . . .You know, that's the problem," he said. "You start listening to the outside world, and then you're screwed. So it just took me a long time to grow up. I think I was buying into, or I felt obligated and it was my fault to feed that image of bachelor, cocksman guy. I really wasn't that guy, but I felt like I had to puff that up at times."

When Stamos shed that image, he got serious about life and love, and this opened up many possibilities for him, including marriage and fatherhood. "Especially with a child now, you start to realize your mortality," he added.

Watch the "Salon Talks" interview with Stamos hereor read the transcript below.

This interview has been lightly edited for length and clarity.

What drew you to doing this series?

Having a show with this many women in it, first of all. Strong women. And the value of a guy like Korn, who's sort of releasing his assumptions and his preconceived ideas of these girls and connecting with them. It just breaks down every stereotype. When we start the thing, he's resistant to the idea that it's going to be a revolutionary experience for him. To him it's a step down.

There was a couple of articles before the show even came out. It was like, "Oh, women's basketball. Why are they putting it out?" They're not . . . We're building it up and we're shining a light on it. But in his mind it was. I mean, he comes from college basketball and it just starts with him waking up to the idea that these assumptions are old and they're dated, and he's got to get with it.

The line, just in general in life, as you know in our society now, is moving. And if you're not paying attention, then it's your fault. Everybody has a voice now, and people are speaking and they're saying, "I don't feel equal." "I don't feel noticed." "I don't feel that I matter." We have to listen. It's our job. Not to judge you. We don't know how they feel.

I feel the show has really been . . . Looking back at it, I didn't realize it that much when I was shooting it. I kind of did, but I didn't realize that the timing would be so good and the impact would be so important at this moment.

Somehow you've had tremendous sustaining power in the industry, which is a great accomplishment.What do you think is your magic formula for balancing doing the job and keeping yourself looking the part? Do you have any tips?

I'm glad that all that comes off. Because it took me a long time to shed this dumb Peter Pan syndrome that I had. I think a lot of it came from outside . . . You know, that's the problem. You start listening to the outside world and then you're screwed. So it just took me a long time to grow up. I think I was buying into, or I felt obligated and it was my fault, to feed that image of bachelor, cocksman guy. I really wasn't that guy, but I felt like I had to puff that up at times to I think a lot of people live vicariously through that kind of image. But it really wasn't me. So once I shed that, I just started to really get serious about life.

I've always sort of taken care of myself. I don't do a lot of creams and ointments and stuff, but I do have very good genes. I had to sober up about five-and-a-half years, almost six years now. And that did a lot for me. I mean, that opened up my life, really. It opened up marriage and a child and a solid career. So that was a big turning point for me.

It just takes a long time. It took me a long time anyway, to just not try to be funny all the time and not try to charm the pants off I was going to a shrink, or I go once in a while, he said, "Stop trying to charm the world. You did it already. Just relax."

It's just so hard. And I'm doing that in this character, I think. It's taken me a long time just to not move around and trust the writing and not have to do s**t, you know, stuff. So I think that's part of it.

Then my dad was a great example of discipline and being a good man, a hardworking man. He had fast food restaurants that he was grooming me to take over. I would watch him treat the bus boy in the back washing dishes, the same way that he treated his best customer. I didn't really realize it until years later that that's what he was doing. And that's what I try to do. I'm interested in people. But I think maybe that's part of the that's helped the longevity.

"Big Shot" starts streaming on Friday, April 16 on Disney+.

See the article here:
John Stamos' secret to longevity is to "stop trying to charm the world" - Salon

Read More...

British royals’ longevity is a full three decades longer than their subjects’ – The Mandarin

April 17th, 2021 1:54 am

In the U.K. it is customary to receive a personalised message from the queen on your 100th birthday such is the relative rarity of reaching the milestone.

Prince Philip was just a couple months off, dying at the age of 99 years and 10 months on April 9, 2021. The last notable royal death before his was that of the queen mother in 2002. She was 101 years old.

Reaching such a ripe old age isnt uncommon among the British ruling family in fact, my analysis shows that on average they live an additional 30 years compared with their subjects.

I looked at the duration of life of the last six British monarchs, along with the longevity of their spouses and children in total 27 royals. What it reveals is a fascinating and familiar story for those of us who study aging and longevity for a living. As a professor of epidemiology and biostatistics, I had previously observed the exact same phenomenon among U.S. presidents they also tend to live decades longer than the general population they serve.

The ruling U.K. monarchs from Queen Victoria onward lived an average of 75 years. And this longevity will continue to rise with each day that Queen Elizabeth II currently age 95 lives. Their spouses survived even longer, reaching an average age of 83.5 years. If Victorias husband Prince Albert, who died of suspected typhoid fever at age 42 in 1861, is removed from the equation, the average duration of the life of the spouses of the monarchs was an astonishing 91.7 years.

By contrast, the average life duration of the wider U.K. population for the years the monarchs were born throughout this period was only 46 years, according to figures from the Human Mortality Database. For example, the typical life expectancy at birth for a female in the U.K. in 1819 was just under 41 years. Queen Victoria, also born in 1819, was 81 when she died. By the time Elizabeth II was born in 1926, life expectancy at birth for females in the U.K. had risen to 62 the queen has already surpassed that by some 33 years.

Such differences in lifespan with some members of the royal family living to an age double that expected of the general population are considered in aging circles to be extremely large, but not uncommon.

Lifespan differences of this magnitude are the result of a combination of genetic as well as social and behavioural influences.

No one can live long without first having won the genetic lottery at birth. To maximise the chances of achieving exceptional longevity upward of 85 years old you must begin by being lucky enough to have long-lived parents. But even for those blessed with the gift at birth of the potential for a long life, this is no guarantee youll outlive your contemporaries.

Get the Juice -the Mandarin's free daily newsletter delivered to your inbox.

Youll also receive special offers from our partners. You can opt-out at any time.

The next challenge is to avoid behaviours that shorten life. That list is long it is a lot easier to shorten life than extend it but among the most well known are smoking, eating in excess and lack of exercise.

And then there is the influence of poverty and privilege. Being born into or living in poverty has been shown to be one of the most important factors that shortens lifespan and it is here that perhaps the royals have the greatest advantage.

Further evidence of privilege being a crucial ingredient in the recipe for exceptional longevity can be seen in the fact that the children of the last six U.K. monarchs that died from natural causes lived an average of 69.7 years. This is some 23 years more than the average age of British subjects over that period.

Put simply, British monarchs and their families live so much longer than their subjects for the same reason other subgroups of the population across the globe live longer than contemporaries born in the same year: privilege over poverty. A famous study conducted in Manchester, England, in 2017 demonstrated vast differences in life expectancy depending on the conditions of where people lived. Access to higher education and economic status was directly correlated with longer life, while lower education, income and poverty were linked to shorter lives.

In the U.S., similar studies of life expectancy by county, census tract and zip code demonstrated the same phenomenon. In fact, there are multiple instances of dramatic differences in longevity among people living as close as across the street from each other caused by differences in poverty and privilege.

Differences in duration of life are first defined by genetics, but it is then heavily mediated by education, income, health care, clean water, food, indoor living and working environments, and the overall effects of high or low socioeconomic status.

The long life of Prince Philip is a cause for celebrating the progress of medical science in being able to keep people alive for longer. But it is in part the result of a privilege denied to many and a reminder that humanity has a long way to go to equalise the chances of living a long life.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

READ MORE:

The Queens gambit: New evidence shows how Her Majesty wields influence on legislation

Original post:
British royals' longevity is a full three decades longer than their subjects' - The Mandarin

Read More...

4 Ways to Achieve Longevity in the Cannabis Business – Green Entrepreneur

April 17th, 2021 1:54 am

The industry is a marathon, not a sprint. Here's how to finish strong.

Learn how to get your business funded in the Cannabis economy!

April16, 20214 min read

Opinions expressed by Entrepreneur contributors are their own.

All signs point to 2021 being the year to place your bets on cannabis. With the recent legalization measures in several US states and the reclassifying of cannabis by the United Nations, the industry's stigma is diminishing at an ever-increasing rate. This has encouraged legislators to hasten its legalization at the state level (where it is not already fully legal), and more importantly, at the federal level, where there appears to be a change of heart toward cannabis that followed the new administration into power. While we evolve at a staggering rate, both newcomers and industry veterans will need to focus on longevity and a healthy growth plan to succeed.

As we head into one of the most exciting years for our industry yet, here are our essential tips for success:

Cannabis is popping up everywhere - and is available in nearly everything you can eat, drink and put on or in your body, becoming the hottest commodity of our generation. This means professionals from numerous non-cannabis industries are showing interest, often with the assumption that their experience will translate to a successful brand. But there are nuances in the cannabis industry that often trip up even the most experienced executive new to this industry.

It's essential to do your homework and understand all aspects of this highly interconnected industry, from the plant itself to cultivation to the manufacturers, and eventually, the consumers. The power of knowledge remains essential in the inner workings of cannabis companies obtaining longevity.

Cannabis companies that achieve success have diversified their leadership teams with experts from various domains, including science, medicine, and foodnotjustcannabis. These brands have strategic strength and staying power.

Branching out and seeking these specialties can have a profound impact on gaining a broader perspective on your brand's potential, and ultimately, your market share. By ensuring a diverse set of skills in your team, you will increase your brand's longevity as the industry's landscape evolves.

When I first moved into the cannabis space, I was opposed to vertical integration for several reasons: owning cultivation infrastructure was daunting, capital-intensive, and inefficient. But I've come to appreciate that there is value in owning and controlling multiple elements of the supply chain. I've realized that achieving multi-vertical integration (downstream of cultivation) is an alternative and more attainable goal and eliminates a brand's reliance on a third party's success.

In a nascent industry like cannabis, companies that integrate multiple aspects of the supply chain into their business models have a greater likelihood of success than those who don't. Owning multi-verticals, such as manufacturing, distribution, and retail infrastructure, all under one umbrella, creates self-sufficiency and greater control over a brand's destiny.

We are now facing a new age of cannabis, where the support of an established Consumer Packaged Goods (CPG) player can be the determining factor for a cannabis brand to evolve. CPG parties, however, are notoriously unaware of the ins and outs of cannabis values, so much so that they often result in little (to no) appreciation for the spirit of the plant, and ultimately, do not understand what experienced cannabis parties offer. The challenge, however, is blending a more disciplined CPG approach to the ritualized legacy of cannabis culture.

For any modern cannabis company to secure longevity and growth, they must face this tension and commit to finding the balance of these otherwise dichotomous approaches. By attaining synergy between the cannabis professionals and the CPG players, your cannabis brand will ensure a blended culture, and ultimately, a healthy growth plan.

By implementing these four steps, your business has a greater chance of overcoming the many challenges that defeat well-intentioned cannabis companies today.

View original post here:
4 Ways to Achieve Longevity in the Cannabis Business - Green Entrepreneur

Read More...

Ron Price’s coaching longevity will be tough to eclipse – Los Angeles Times

April 17th, 2021 1:54 am

Ron Price is a walking, talking legend in Southern California. Across seven decades and some 60 years, Price has been coaching football.

He was on the same fields with City Section coaching Hall of Famers Chris Ferragamo (Banning), Jack Neumeier (Granada Hills) and Gene Vollnogle (Carson) and players John Elway, Rod Martin and Warren Moon. He was the health teacher for Washington Preps Paul Knox while at Hamilton and coached against Venice coach Angelo Gasca when Gasca was a high school quarterback.

Hes been a head coach at Crenshaw, Palisades and Fairfax. He started as an assistant coach in 1961 at Brentwood Military Academy and now is an assistant coach at St. Monica.

This will be the last decade and could be the last year, he said. When youre 84, youre like all the great athletes day to day. I feel great. As long as I can do it, Ill do it.

Coaching the offensive line has been Prices specialty. Coaching anything has been his life-long passion.

Ive always enjoyed it, he said. Its always been fun. Its what I wanted to do from the time I was a teenager.

Newsletter

Get our high school sports newsletter

Prep Rally is devoted to the SoCal high school sports experience, bringing you scores, stories and a behind-the-scenes look at what makes prep sports so popular.

Enter email address

Sign Me Up

You may occasionally receive promotional content from the Los Angeles Times.

Many years ago his father, who was a doctor, questioned his professional pursuit while living in Chicago. His dream was to coach the Chicago Bears.

He used to look at me and laugh. He said, The only Bears youll ever be coaching will be in a zoo.

Price has been coaching so long that a couple players at St. Monica are sons of former players he coached. St. Monica head coach Geoff McArthur played for him at Palisades.

Gasca said of Prices seven-decade coaching stint:

An incredible accomplishment. Hes an amazing person who I greatly admire and respect. I competed against his teams as a high school player. Competed against him as a coach. Then had the fortune to work with him for many years. Im better for it and so are the lives of all the people whose lives he touched. An icon.

With apologies to Texas and Florida, the best high school football game of the 2020-21 school year will take place Saturday night at Santa Ana Stadium when Bellflower St. John Bosco (5-0) takes on Santa Ana Mater Dei (4-0) to decide the spring Trinity League championship.

If St. John Bosco coach Jason Negro and Mater Dei coach Bruce Rollinson could combine their teams and take them on the road to face any and all challengers, theyd be unbeatable.

The lines are big, powerful and mobile. The running backs are fast and big-play weapons. The quarterbacks are young but future college players. The secondaries are aggressive and fearless.

It has all the makings of another classic game. The last one between these two schools saw St. John Bosco roar back from a seemingly insurmountable 28-5 deficit in 2019 to win 39-34 in the fourth consecutive Southern Section Division 1 final involving the two schools.

For this game, Mater Deis defense will present a lot more problems for the Braves quarterback duo of Pierce Clarkson and Katin Houser. Its probably a good situation that St. John Bosco is still alternating quarterbacks every series, because that gives the Braves options to take advantage of each quarterbacks different strengths.

The big clue about which team will win should come early. Its going to be about which team can run the ball most effectively to open up the passing game.

So break out the popcorn on Saturday night, lay back on the couch at 7 p.m. and turn on Bally Sports West. You can hear Petros Papadakis and Greg Biggins raving about how many future five-star recruits are in the game. MaxPreps.com says theres 59 players on the rosters who have FBS offers. It will be the most entertaining high school football game in America

Joshua Koo, a 16-year-old junior at Cerritos High, shot a final round of 10-under-par 62 to win the two-day Toyota Tour Cup junior golf tournament in Palm Desert on Sunday. He had eight birdies and an eagle.

I hadnt been hitting that well recently and was working on my putting, he said. That day everything clicked. It was a really fun round.

Visit link:
Ron Price's coaching longevity will be tough to eclipse - Los Angeles Times

Read More...

Tolerance of the Intolerable and the Longevity of Trump Paraphernalia – Hyperallergic

April 17th, 2021 1:54 am

CHARLOTTE, North Carolina Over the past few years I have been travelling to the Carolinas to spend the winter holidays with my parents who split the colder months between Charlotte, North Carolina, and Myrtle Beach, South Carolina. This year, while traversing the small country roads between these two cities, I noticed a number of pop-up Trump Centers sandwiched between the usual CBD boutiques, diversity-targeted military recruiting ads, homemade liquor signs, and lottery ads. These self-proclaimed Trump Centers are typically found in half-abandoned shopping centers, corners of souvenir shops, and surrounded by dying businesses.

During Trumps time in office I didnt have the strength to enter these places.

I had experienced firsthand how nasty the media and domestic affairs could be, particularly since I had created together several artworks in reaction to the administration. One artwork, a satirical-anti-monument, ended up going viral, shared by both left-and right-wing users, causing a backlash of hate mail from both communities.The work even provoked anonymous arsonists to burn the artwork down this event, combined with hateful threats, weakened and depleted me emotionally.But, over the past weeks, I decided to retrace my steps through the Carolinas to investigate these centers more closely. This decision took me down a rabbit hole of dark tourism and nationalist identity.

Initially, I was astonished to discover that these shops have stayed open, even months after the end of Trumps presidency. I was also surprised by the diverse backgrounds of the shop owners themselves. The largest Trump Center I visited was in South Carolina, operated by a family of Pakistani immigrants, while another in North Carolina was run by a couple of Mexican descent. However, the smaller and more sinister-feeling shops were typically manned by older white men or bikers.

As you might imagine, in my conversations with the owners, I found them to be skeptical of the government establishment, pro-gun, anti-media, down on their luck, and growing more paranoid. The topics of the conversations usually centered around the idea that the election was stolen from Trump, or the possibility he is still actually the president. These brief discussions would start with me asking how do you feel the election went? to which various employees responded:

Supporting Trump and clinging to his presidency has become a kind of alternative-reality game, or a pseudo religion for these Trump supporters. They have a kind of missionary zeal, regardless of heritage. Probing into the depths of denial and cult-like worship, combined with being exposed to so many confederate flags, blatant evidence of racism, and extreme xenophobia has made me feel sick and sad again.

Weve all seen how Trumps presidency emboldened radical nationalists and white supremacists. Their numbers grow with a supportive tweet from him, and in return, the horror of their actions diminished, obscured, or recast as patriotism. Even the darkest sentiments casually conserved on racist T-shirt designs, 100% southern grown, picked by yo momma.

They are so very certain of their righteous place in history and their future victory parade that they are still keeping the gift-shop open.

As arts communities around the world experience a time of challenge and change, accessible, independent reporting on these developments is more important than ever.

Please consider supporting our journalism, and help keep our independent reporting free and accessible to all.

Become a Member

Read the original post:
Tolerance of the Intolerable and the Longevity of Trump Paraphernalia - Hyperallergic

Read More...

Could a simple pill improve longevity and slow the aging process? – Newshub

April 17th, 2021 1:54 am

"So actually when we exercise and we don't eat, these genes come on and act as traffic lights - and they are traffic cops that direct the body to repair itself and protect itself from diseases and aging."

Peter Dearden, a professor of biochemistry at the University of Otago, says although we're starting to understand how longevity and aging works in humans, we're really "a long way away" from putting that into a pill.

"You can improve longevity in mice, but no one has shown we can do that in humans yet," he tells The Project on Tuesday.

Kiwi aging expert Greg Macpherson says we should adopt better lifestyle choices as well as add in a few extra supplements.

"We can get some lessons from places called the 'blue zones' and blue zones are places around the world where people have lived and get to a hundred much more than the rest of us," he told The Project.

"And these people do these things like they have a plant-based diet, they exercise a bunch and we can take lessons from that and add in a few extra supplements that are available to us now that weren't available to previous generations.

"And these things are going to see us be healthier for a lot longer and that's going to have some effect on the amount of time we're around."

Macpherson's book Harnessing the Nine Hallmarks of Aging addresses the science of aging.

More:
Could a simple pill improve longevity and slow the aging process? - Newshub

Read More...

How Prince Philip and Queen Elizabeth outlived the average British subject by three decades – MarketWatch

April 17th, 2021 1:54 am

In the U.K. it is customary toreceive a personalized message from the queenon your 100th birthdaysuch is the relative rarity of reaching the milestone.

Prince Philip was just a couple months off,dying at the age of 99 years and 10 monthson April 9, 2021. The last notable royal death before his was that of thequeen mother in 2002. She was 101 years old.

Reaching such a ripe old age isnt uncommon among the British ruling familyin fact, my analysis shows that on average they live an additional 30 years compared with their subjects.

I looked at the duration of life of the last six British monarchs, along with the longevity of their spouses and childrenin total 27 royals. What it reveals is a fascinating and familiar story for those of us who study aging and longevity for a living.

Being born into or living in poverty has been shown to be one of the most important factors that shortens lifespanand it is here that perhaps the royals have the greatest advantage.

As aprofessor of epidemiology and biostatistics, I had previouslyobserved the exact same phenomenon among U.S. presidentsthey also tend to live decades longer than the general population they serve.

The ruling U.K. monarchs from Queen Victoria onward have lived an average of 75 years. And this will continue to rise with each day that Queen Elizabeth IIcurrently age 95lives. Their spouses survived even longer, reaching an average age of 83.5 years. If Victorias husband Prince Albert, whodied of suspected typhoid feverat age 42 in 1861, is removed from the equation, the average duration of the life of the spouses of the monarchs was an astonishing 91.7 years.

By contrast, the average life duration of the wider U.K. population for the years the monarchs were born throughout this period was only 46 years, according to figures from theHuman Mortality Database.

For example, the typical life expectancy at birth for a female in the U.K. in 1819 was just under 41 years. Queen Victoria, also born in 1819, was 81 when she died. By the time Elizabeth II was born in 1926, life expectancy at birth for females in the U.K. had risen to 62the queen has already surpassed that by some 33 years.

Such differences in lifespanwith some members of the royal family living to an age double that expected of the general populationare considered in aging circles to be extremely large, but not uncommon.

Lifespan differences of this magnitude are the result of a combination ofgenetic as well as social and behavioral influences.

No one can live long without first having won the genetic lottery at birth. To maximize the chances of achieving exceptional longevityupward of 85 years oldyou must begin by beinglucky enough to have long-lived parents. But even for those blessed with the gift at birth of the potential for a long life, this is no guarantee youll outlive your contemporaries.

The next challenge is to avoid behaviors that shorten life. That list is longit is a lot easier to shorten life than extend itbut among the most well known aresmoking, eating in excess and lack of exercise.

And then there is the influence of poverty and privilege. Beingborn into or living in povertyhas been shown to be one of the most important factors that shortens lifespanand it is here that perhaps the royals have the greatest advantage.

Further evidence of privilege being a crucial ingredient in the recipe for exceptional longevity can be seen in the fact that the children of the last six U.K. monarchs that died from natural causes lived an average of 69.7 years. This is some 23 years more than the average age of British subjects over that period.

Put simply, British monarchs and their families live so much longer than their subjects for the same reason other subgroups of the population across the globe live longer than contemporaries born in the same year: privilege over poverty. A famousstudy conducted in Manchester, England, in 2017demonstrated vast differences in life expectancy depending on the conditions of where people lived. Access to higher education and economic status was directly correlated with longer life, while lower education, lower income, and poverty were linked to shorter lives.

In the U.S., similarstudies of life expectancy by county,census tractand ZIP Code demonstrated the same phenomenon. In fact, there are multiple instances of dramatic differences in longevity among people living as close as across the street from each othercaused by differences in poverty and privilege.

Differences in duration of life are first defined by genetics, but it is then heavily mediated by education, income, health care, clean water, food, indoor living and working environments, and the overall effects of high or low socioeconomic status.

The long life of Prince Philip is a cause for celebrating the progress of medical science in being able to keep people alive for longer. But it is in part the result of a privilege denied to many and a reminder that humanity has a long way to go to equalize the chances of living a long life.

S. Jay Olshanskyis a professor of epidemiology and biostatistics in the School of Public Health at the University of Illinois at Chicago. He is a research associate at the Center on Aging at the University of Chicago and at the London School of Hygiene and Tropical Medicine, and is chief scientist at Lapetus Solutions, Inc.

This commentary was originally published by The ConversationLong live the monarchy! British royals tend to survive a full three decades longer than theirsubjects.

More:
How Prince Philip and Queen Elizabeth outlived the average British subject by three decades - MarketWatch

Read More...

Monthly Life Annuity Benefits Decrease in the Longevity Era – The Korea Bizwire

April 17th, 2021 1:54 am

SEOUL, April 13 (Korea Bizwire) The value of life annuity benefits has decreased sharply over the past twenty years as the average lifespan increased.

The age with a mortality rate of higher than 5 percent rose to 80 for men and 84 for women in 2019 from 73 and 78 in 2000, according to the latest report by the Korea Insurance Research Institute.

The extension of the average lifespan has led to an increase in the number of life annuity benefit receivers, resulting in a decline in the amount of per-capita life annuity benefits.

The report said that for a life annuity product that pays a benefit every month to male beneficiaries until their death if they make a lump-sum payment of 100 million won (US$88,920) at the age of 60, those who subscribed to the product in 2000 could receive 482,000 won per month.

However, the amount of monthly benefit dropped by 23.8 percent to 367,000 won for those who subscribed to the product in 2019.

The amount of monthly benefit for female beneficiaries also decreased by 19.9 percent from 380,000 won to 304,000 won.

Image Credit: Yonhap / photonews@koreabizwire.com

See original here:
Monthly Life Annuity Benefits Decrease in the Longevity Era - The Korea Bizwire

Read More...

NationsBuilders Insurance Services, Inc. (NBIS) Awarded Longevity Award by SC&RA for 25 Years of Service – PR Web

April 17th, 2021 1:54 am

NBIS Celebrates 25 Years of Service to the SC&RA

ATLANTA (PRWEB) April 12, 2021

SC&RAs Longevity Awards are presented to member companies for their longtime support and dedication to the Association and its mission. NBIS was recognized with the 25 Years Award.

Throughout its membership, NBIS has been the endorsed provider of property casualty insurance to the members of the SC&RA. NBIS serves SC&RA members and the industry with unparalleled Risk Solutions developed alongside SC&RA members to be right sized for the industry. Every policyholder has access to our Risk Management Support System (RMSS) and able to take advantage of resources and partnerships developed to support the safety culture, manage & reduce claims and increase compliance with industry regulations & standards.

We are proud of our partnership and endorsement with the SC&RA and its members commented Bill Tepe, President & CFO of NBIS. Adding, Together, NBIS and the Association worked to improve the risk profile of the member companies and the industry as a whole.

As a leading provider of Risk Management & Insurance Solutions, NBIS specializes in providing insurance solutions for the Crane & Rigging, Concrete Pumping and Specialized Transportation/Heavy Haul Industries.

Want to learn more about NBIS Coverages and the Risk Management Support System? Contact us today at 870.866.RMSS

To learn more about NBIS insurance & risk solutions, visit us on the web: http://www.NBIS.com

Media Contact for NBIS: Lisa McAbee, Marketing Director (770) 257-1707 lmcabee@nbis.com

About NBISNBIS is the Premiere provider of Insurance & Risk Management Solutions to the heavy construction industry and the exclusively endorsed provider for the Specialized Carriers & Rigging Association (SC&RA). Providing coverage and Risk Management Services that works for you to prevent losses and give your company the best fighting chance in the event of a claim. For more information about NBIS, please visit: http://www.NBIS.com.

About SC&RAThe Specialized Carriers & Rigging Association (SC&RA) is an international trade association of more than 1,400 members from 46 nations. Our members are involved in specialized transportation, crane and rigging operations, machinery moving and erecting, industrial maintenance, millwrighting, manufacturing, concrete pumping, and rental services. SC&RA helps members run more efficient and safer businesses by monitoring and affecting pending legislation and regulatory policies at the state and national levels and researching and reporting on safety concerns and best business practices. For more information, visit scranet.org.

Share article on social media or email:

See the original post:
NationsBuilders Insurance Services, Inc. (NBIS) Awarded Longevity Award by SC&RA for 25 Years of Service - PR Web

Read More...

Bradford City duo inspired by Weaver longevity at Harrogate – Bradford Telegraph and Argus

April 17th, 2021 1:54 am

AS HE watched Eccleshill lift the West Riding County Cup at Valley Parade in 2014, Conor Sellars could not have imagined that he would be back one day in the home dug-out.

And it might have also been stretching it to think that Harrogate, beaten by a last-minute penalty that night, would now be on an equal footing with City in League Two.

They were in the National League North when Sellars spent a season playing at Wetherby Road.

But there were some experienced names in the line-up, including former City midfielder Adam Bolder and Scotland international and current Portsmouth goalkeeper Craig McGillivray.

Ive played a few reserve games at Valley Parade but I do remember that night, recalled Citys joint boss. It was nice to be playing there but it was a tough one to take losing 1-0 (to a last-minute penalty).

We had players who had played in the Championship or maybe the Premier League and obviously Craig went on to the Football League and is having a good career.

There were a lot of players from different backgrounds who had played at different levels.

I think Harrogate have always attracted good players along the way, although maybe not myself.

Simon Weaver was his manager at the time and will still be there on the sidelines for Citys Saturday lunchtime visit as he approaches his 12th anniversary next month at the Harrogate helm.

It is a remarkable achievement, even more so in the hire em, fire em environment of the modern game and something that new managers like Sellars and Mark Trueman can aspire to.

Sellars added: Its brilliant. Mark and I obviously know Simon and how long hes been there.

I had some good discussions with him while I was a player there and enjoyed working with him.

I used to really like his desire and how committed he was.

We were part-time at the time in Conference North but he lived and breathed it. His intensity in his work was great to see.

Success is maybe not just an immediate thing. Its something built over years of hard work and putting your identity and stamp on it.

We have to get results, we have to show intent and improve. We know that.

But we also want to build something long term at this club and hopefully were given the chance to do so.

Could they still be in the job after a dozen seasons like Weaver?

Why not? he said. But thats why it is such a good story seeing Harrogate go up the leagues.

This year was a massive test for them but I think theyve shown everybody that they deserve to be in this division.

Its been fantastic to see the development. When I was there, they always spoke about moving forward and trying to get into the National League and then into the EFL and theyve done that.

The midweek hiccup against Crawley has left City four points adrift of the play-offs. But Sellars insists they are still in the mix going into a six-game shoot-out.

Its hard to predict and I wouldnt want to do that. It can go in lots of different directions.

We just hope it can go in the most positive one.

We have confidence that we can do that but were also realistic to know that everything is not going to be a smooth as wed like.

From the day that we took over until now, we feel were in a good position. Its a bonus that were trying to get into the play-offs.

But again, I think it shows the hard work of everybody involved.

Continued here:
Bradford City duo inspired by Weaver longevity at Harrogate - Bradford Telegraph and Argus

Read More...

How to live longer: A diet rich in flavonoids linked to a lower risk of cancer – study – Express

April 17th, 2021 1:54 am

What counts as flavonoids?

Flavonoids are mainly found in fruits, vegetables and other plant-based foods but also crop up in red wine and dark chocolate.

"The general rule is that the more colourful a fruit or vegetable is, the higher the level of flavonoids it contains," explains Holland and Barrett.

As the health body explains, there are five main types of flavonoids that contain various benefits, each of which are found in different foods.

These are:

Flavanols

They are commonly found in kale, peaches, tomatoes, onions, lettuce, tea, grapes, red wine, blueberries, and other fruit.

Flavan-3-ols

Nutrient-rich flavan-3-ols can be found in lots of foods. These include white, green, and black tea, as well as apples, grapes, strawberries, blueberries and even cocoa products, such as dark chocolate.

Flavones

Like all flavonoids, flavones are praised for their antioxidant properties. Citrus fruits like lemons, grapefruit, limes and oranges are familiar sources of flavones as are celery, parsley, and hot peppers.

Isoflavones

More research is needed around isoflavones, but experts believe this type of flavonoid can help with the bodys hormone balance. Isoflavones are richest in soy products along with peanuts, pistachios, and fava beans.

Anthocyanins

The last flavonoid on our list, anthocyanins. Youll commonly find these flavonoids in the outer skin of various berries, including red and purple grapes, blackberries, strawberries, blueberries, cranberries and even red wine.

Continued here:
How to live longer: A diet rich in flavonoids linked to a lower risk of cancer - study - Express

Read More...

Page 182«..1020..181182183184..190200..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick